Xcout IntelGossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Subscribe to see Gossamer Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Gossamer Bio, Inc. at a glance
Gossamer Bio, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (GOSS) with a market capitalisation of $56.9M. Xcout tracks 27 named people at Gossamer Bio, Inc., including Bryan Giraudo (Chief Operating Officer & Chief Financial Officer). Xcout recorded 3 job postings from Gossamer Bio, Inc. in the last 90 days.
Gossamer Bio, Inc. leadership
- Bryan GiraudoChief Operating Officer & Chief Financial Officer
- Robert SmithChief Commercial Officer
- Caryn L. PetersonChief Development Officer
- Faheem HasnainCo-Founder, Chief Executive Officer, President & Chairman
- Deanna WeberExecutive Vice President of Human Resources
- Conor O'DonovanSenior Vice President of Regulatory Affairs
21 more named people on record for Gossamer Bio, Inc., with roles, board committees and tenure — see the full roster →
Gossamer Bio, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $230M | — | |
| Seed | $100M | 2 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Gossamer Bio, Inc.
Xcout recorded 3 job postings from Gossamer Bio, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Gossamer Bio, Inc.'s hiring signals →
Investors
Gossamer Bio, Inc. competitors
A few of Gossamer Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Pahr Therapeutics, Inc. is a biotechnology company focused on developing new treatments for pulmonary arterial hypertension (PAH). The company recently raised $14 million in seed funding to support its therapeutic development efforts.
Sunterra Bio is a biopharmaceutical company focused on developing inhaled small-molecule therapies for rare pulmonary diseases. Headquartered in Carlsbad, California, the company advances targeted treatments for respiratory conditions.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, with additional operations in San Diego, California. The company focuses on the discovery and development of novel biopharmaceuticals for cardiovascular and other severe diseases.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Get Gossamer Bio, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Gossamer Bio, Inc. in Xcout Intel
- 27 named people with titles, LinkedIn and board committees
- 2 funding rounds before the IPO with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access